VanEck Vectors Biotech ETF
Latest VanEck Vectors Biotech ETF News and Updates
Pfizer’s Medivation Acquisition: What You Need to Know
On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.
Third Point Partners ups stake in Amgen
The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
Why Sesen Bio Stock Jumped Over 37% this Week
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.
Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.
Recommendations for Shire as of October 30
Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.
Amgen: Expect Nearly Flat Revenues in Q3
New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.
Allergan’s Q3 2018 Estimates: Revenue Decline Expected
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Analysts Are Mostly Positive on Neurocrine Biosciences
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
Allergan’s Developments in September
On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.
A Look at Incyte’s Valuation on August 22
On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.
Examining Amgen’s Revenue Trend in Q2 2018
Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.
What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.
Shire’s Q2 2018 Earnings Beat Analyst Estimates
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.
A Look at Ionis’s 3Q17 Revenue Stream
Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.
How Was Incyte’s Revenue Stream in 3Q17?
Incyte’s total product royalty revenue was $44.5 million in 3Q17, a rise compared to $29.6 million in 3Q16.
Benefitting from IBB’s Lower Expense Ratio
The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.
How Gilead’s HIV and HBV Portfolios Performed in 2Q17
Gilead Sciences’ (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.
How Akcea Therapeutics’ Volanesorsen Performed in 2Q17
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.
Understanding Incyte’s 2Q17 Revenue Stream
Incyte’s 2Q17 revenue growth was driven by the increased demand for Jakafi.
What’s Allergan’s Valuation after 2Q17 Earnings?
Allergan reported an 8.8% increase in its 2Q17 revenues to $4.0 billion as compared to $3.7 billion in 2Q16.
Analysts’ Recommendations for Regeneron in July 2017
In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.
Inside Allergan’s Developments in 2Q17
Allergan (AGN) is a US-based pharmaceuticals company that deals in over-the-counter products, eye care products, and aesthetics products.
A Look at Allergan’s Performance in 2Q17
Allergan Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: US Specialized Therapeutics, US General Medicine, and International. Stock price performance Allergan’s stock price has risen ~1.4% in 2Q17, and 15.0% year-to-date as of July 7, 2017. […]
Investor Update: Incyte’s Key Developments in 1Q17
Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.
Developments for Ionis Pharmaceuticals after 1Q17
Ionis’s recent developments As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. Corporate developments In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China. In […]
Inside Allergan’s 1Q17 Results: Revenue Streams
Allergan (AGN) released its 1Q17 earnings on May 9, 2017, reporting a growth of 5.1% and revenues of ~$3.6 billion, as compared to $3.4 billion in 1Q16.
Why These Collaborations Are Important to Incyte
Incyte’s (INCY) Jakafi is distributed in the US markets through its network of specialty pharmacy providers and wholesalers for direct delivery to patients or patients’ pharmacies.
What’s the Outlook for Gilead Sciences?
Analysts are estimating that Gilead Sciences (GILD) will generate EPS (earnings per share) of $2.62 on sales of $7.1 billion in 4Q16.
Gilead Sciences’ Valuation Compared to Its Peers
As of December 30, 2016, Gilead Sciences (GILD) was trading at a forward PE multiple of ~6.9x compared to the industry average of 12.3x.
Why Valbenazine Studies Seem Promising
In Neurocrine Biosciences’ (NBIX) phase three trial Kinect-3, investigational therapy Valbenazine has managed to demonstrate statistically significant improvement.
Epclusa: Gilead Sciences’s Pan-Genotype Product
With its costly HCV drugs, Gilead Sciences (GILD) has one of the highest net margins in the biotechnology industry.
Understanding Allergan’s 3Q16 Revenue Stream
As we discussed earlier, Allergan (AGN) reported revenues of $3.62 billion in its 3Q16 results—more than 4.5% revenue growth in 3Q16.
BioMarin’s Business Model and Its 3 Sources of Revenue
Let’s discuss BioMarin’s business model. It derives revenue from three sources, including product revenue. The latter accounts for ~98% of total revenue.